Safe Care CommitmentExpert care for in-person and virtual visits; Hospital visitor policyLearn more
Dr. Erica S. Shenoy is an Associate Physician at the Massachusetts General Hospital where she specializes in the evaluation and management of infections among both hospitalized and ambulatory patients. Dr. Shenoy sees patients in the Infectious Diseases clinic at the Mass General Main Campus on Mondays, and is available for follow up, initial consultations and second opinions.
Dr. Shenoy is Associate Chief of the Infection Control Unit at Mass General and an Assistant Professor at Harvard Medical School. She is board certified in infectious diseases and internal medicine. She is additionally trained as a health economist. Dr. Shenoy is a principal investigator on several grants and leads an active research team evaluating the clinical, operational and economic impact of infection control strategies for multi-drug resistant organisms.
Dr. Shenoy has a leadership role in the Mass General planning and response to Ebola Virus Disease (EVD) and other special pathogens. She is responsible for development of hospital policies and procedures emerging infectious diseases and has worked closely with staff from across the institution in planning meetings, training, and drills and exercises. As Medical Director of the Mass General Biothreats Care Unit (BCU), one of 10 federally funded special pathogens programs in the United States, Dr. Shenoy is responsible for the overall operations of the BCU, including the implementation of awarded grants. She liaises with the hospital’s Incident Management Team and Hospital Incident Command System as needed.
Clinical Interests:
Treats:
Languages:
Infectious Disease Associates
100 Blossom Street
Boston, MA 02114-2696
Phone: 617-726-3812
Phone: 617-726-8403
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research addresses the clinical, operational and economic impacts of competing Infection Control strategies for important nosocomial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). This involves hospital-based clinical studies, national survey-research, as well as “dry-bench” studies using computer-based simulation modeling. Our team collaborates with colleagues with expertise in computer science and articificial intelligence on risk prediction related to hospital acquired infections. I also collaborate with colleagues on research and implementation of antibiotic allergy evaluations.
